Increased
proteoglycan (PG) deposition is a feature of
airway remodeling in
asthma.
Glycosaminoglycans (GAGs) mediate many of the biological and mechanical properties of PGs by providing docking sites through their
carbohydrate chains to bioactive
ligands; therefore, it is imperative to define structural and metabolic changes of GAGs in
asthma. Using a Brown Norway (BN)
ovalbumin (OVA)-sensitized and -challenged rat model to induce
airway remodeling, we found excessive deposition of
chondroitin/dermatan (CS/DS)-, heparan (HS), and keratan (KS)
sulfate GAGs in the airways and bronchoalveolar lavage cells of OVA-challenged rats.
Disaccharide composition of CS/DS of OVA-challenged rats was significantly different compared with saline-treated (SAL) control rats, with increased levels of 0-, 6-, and 4-sulfated
disaccharides. Increases in the amount and a change in the proportion of CS/DS versus HS GAGs were noted in OVA-challenged rats. The higher content and sulfation of CS/DS
disaccharides was reflected by the increased expression of
xylosyltransferase-I, β1,3-glucuronosyltransferase-I, chondroitin-4, and chondroitin-6
sulfotransferase genes and
protein expression of
xylosyltransferase-I and β1,3-glucuronosyltransferase-I in OVA-challenged rats. Genes encoding the core
proteins of the CS/DS and KS-containing PGs, such as
versican,
biglycan,
decorin, and
lumican, were overexpressed in OVA-challenged rats. Our results suggest that GAG biosynthetic
enzymes may be involved in the altered expression of GAGs in the airways and are potential targets for inhibiting excess PG-GAG deposition and the
airway remodeling process in
asthma.